Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Calidi Biotherapeutics (CLDI) has issued an update.
Calidi Biotherapeutics, Inc. has entered into a Subscription Agreement with accredited investor Dr. Ronald Rigor, selling nearly 699,000 shares and warrants to purchase an additional 600,000 shares, culminating in a $1 million private placement. Dr. Rigor’s investment in subsidiary Nova Cell has also led to him receiving 25% of Nova Cell’s shares and the assignment of certain intellectual property rights. Acknowledging his contributions, Dr. Rigor has been appointed to Calidi’s Scientific and Medical Advisory Board and granted 5,000 stock options. These strategic moves aim to bolster the company’s advancements, leveraging Dr. Rigor’s stem cell expertise.
For a thorough assessment of CLDI stock, go to TipRanks’ Stock Analysis page.